146 related articles for article (PubMed ID: 19169685)
1. SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples.
Conroy A; Stockett DE; Walker D; Arkin MR; Hoch U; Fox JA; Hawtin RE
Cancer Chemother Pharmacol; 2009 Sep; 64(4):723-32. PubMed ID: 19169685
[TBL] [Abstract][Full Text] [Related]
2. The small-molecule CDK inhibitor, SNS-032, enhances cellular radiosensitivity in quiescent and hypoxic non-small cell lung cancer cells.
Kodym E; Kodym R; Reis AE; Habib AA; Story MD; Saha D
Lung Cancer; 2009 Oct; 66(1):37-47. PubMed ID: 19193471
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.
Chen R; Wierda WG; Chubb S; Hawtin RE; Fox JA; Keating MJ; Gandhi V; Plunkett W
Blood; 2009 May; 113(19):4637-45. PubMed ID: 19234140
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma.
Tong WG; Chen R; Plunkett W; Siegel D; Sinha R; Harvey RD; Badros AZ; Popplewell L; Coutre S; Fox JA; Mahadocon K; Chen T; Kegley P; Hoch U; Wierda WG
J Clin Oncol; 2010 Jun; 28(18):3015-22. PubMed ID: 20479412
[TBL] [Abstract][Full Text] [Related]
5. The cyclin-dependent kinase inhibitor SNS-032 induces apoptosis in breast cancer cells via depletion of Mcl-1 and X-linked inhibitor of apoptosis protein and displays antitumor activity in vivo.
Xie G; Tang H; Wu S; Chen J; Liu J; Liao C
Int J Oncol; 2014 Aug; 45(2):804-12. PubMed ID: 24865236
[TBL] [Abstract][Full Text] [Related]
6. The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine.
Walsby E; Lazenby M; Pepper C; Burnett AK
Leukemia; 2011 Mar; 25(3):411-9. PubMed ID: 21212792
[TBL] [Abstract][Full Text] [Related]
7. Anticancer activity and differentially expressed genes in head and neck cancer cells treated with a novel cyclin-dependent kinase inhibitor.
Shin HC; Song DW; Baek WK; Lee SR; Kwon TK; Lee J; Park SH; Jang BC; Park JW
Chemotherapy; 2009; 55(5):353-62. PubMed ID: 19657189
[TBL] [Abstract][Full Text] [Related]
8. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
[TBL] [Abstract][Full Text] [Related]
9. Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells.
Yenugonda VM; Deb TB; Grindrod SC; Dakshanamurthy S; Yang Y; Paige M; Brown ML
Bioorg Med Chem; 2011 Apr; 19(8):2714-25. PubMed ID: 21440449
[TBL] [Abstract][Full Text] [Related]
10. ABCB1 as predominant resistance mechanism in cells with acquired SNS-032 resistance.
Löschmann N; Michaelis M; Rothweiler F; Voges Y; Balónová B; Blight BA; Cinatl J
Oncotarget; 2016 Sep; 7(36):58051-58064. PubMed ID: 27517323
[TBL] [Abstract][Full Text] [Related]
11. Progress in the evaluation of CDK inhibitors as anti-tumor agents.
McInnes C
Drug Discov Today; 2008 Oct; 13(19-20):875-81. PubMed ID: 18639646
[TBL] [Abstract][Full Text] [Related]
12. Coming full circle: cyclin-dependent kinases as anti-cancer drug targets.
Fisher RP
Subcell Biochem; 2010; 50():1-15. PubMed ID: 20012574
[TBL] [Abstract][Full Text] [Related]
13. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
[TBL] [Abstract][Full Text] [Related]
14. The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia.
McElligott AM; Maginn EN; Greene LM; McGuckin S; Hayat A; Browne PV; Butini S; Campiani G; Catherwood MA; Vandenberghe E; Williams DC; Zisterer DM; Lawler M
Cancer Res; 2009 Nov; 69(21):8366-75. PubMed ID: 19826055
[TBL] [Abstract][Full Text] [Related]
15. Chemoproteomics-based kinome profiling and target deconvolution of clinical multi-kinase inhibitors in primary chronic lymphocytic leukemia cells.
Kruse U; Pallasch CP; Bantscheff M; Eberhard D; Frenzel L; Ghidelli S; Maier SK; Werner T; Wendtner CM; Drewes G
Leukemia; 2011 Jan; 25(1):89-100. PubMed ID: 20944678
[TBL] [Abstract][Full Text] [Related]
16. All-trans retinoic acid can intensify the growth inhibition and differentiation induction effect of rosiglitazone on multiple myeloma cells.
Huang H; Wu D; Fu J; Chen G; Chang W; Chow HC; Leung AY; Liang R
Eur J Haematol; 2009 Sep; 83(3):191-202. PubMed ID: 19467017
[TBL] [Abstract][Full Text] [Related]
17. Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Blachly JS; Byrd JC; Grever M
Semin Oncol; 2016 Apr; 43(2):265-73. PubMed ID: 27040705
[TBL] [Abstract][Full Text] [Related]
18. Chemoprevention of mouse intestinal tumorigenesis by the cyclin-dependent kinase inhibitor SNS-032.
Boquoi A; Chen T; Enders GH
Cancer Prev Res (Phila); 2009 Sep; 2(9):800-6. PubMed ID: 19723896
[TBL] [Abstract][Full Text] [Related]
19. Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia.
Chen Y; Germano S; Clements C; Samuel J; Shelmani G; Jayne S; Dyer MJ; Macip S
Br J Haematol; 2016 Nov; 175(4):641-651. PubMed ID: 27469405
[TBL] [Abstract][Full Text] [Related]
20. 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
Krystof V; Cankar P; Frysová I; Slouka J; Kontopidis G; Dzubák P; Hajdúch M; Srovnal J; de Azevedo WF; Orság M; Paprskárová M; Rolcík J; Látr A; Fischer PM; Strnad M
J Med Chem; 2006 Nov; 49(22):6500-9. PubMed ID: 17064068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
